Received Mar 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 34MF9 | — |
second dose of Kinrix; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 6-year-old female patient who received DTPa-IPV (Kinrix) (batch number 34MF9, expiry date 13-FEB-2026) for prophylaxis. Concomitant products included Kinrix. On 19-FEB-2025, the patient received the 2nd dose of Kinrix. On 19-FEB-2025, an unknown time after receiving Kinrix, the patient experienced extra dose administered (Verbatim: second dose of Kinrix ). The outcome of the extra dose administered was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 03-MAR-2025 Nurse called to report that they administered a dose of Kinrix to a 6 years 11 months old female patient on 28 JAN-2025 and then on 19-FEB-2025 the patient received another dose of Kinrix. Patient received the second dose ok Kinrix, which led to extra dose administered.